

## Anti-CD14 Antibody (Atibuclimab)

### Introduction

Atibuclimab is a chimeric monoclonal antibody against CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used in the study of amyotrophic lateral sclerosis. Atibuclimab can alleviate LPS-induced symptoms and strongly inhibit LPS-induced pro-inflammatory cytokine release, while only delaying the release of anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist.

### Product parameters

Alternative Names	IC-14, IC14
Target Accession	P08571
Target	CD14
CAS number	2417175-94-9
Molecular Weight	145.3 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CD14, Fc Tag at 2 ug/mL can bind Anti-CD14 Antibody (Atibuclimab), EC50=0.0249 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

